Monday, 10 August 2020

Merck pays Bionomics $172mn for pain molecules

01 August 2013 | News | By BioSpectrum Bureau

Good news for chronic pain patients - Bionomics pays $172mn to Merck to commercialize chronic pain molecules

Good news for chronic pain patients - Bionomics pays $172mn to Merck to commercialize chronic pain molecules

Singapore: Bionomics entered in an agreement with Merck, which is also known as Merck Sharp and Dohme outside the US and Canada, to discover and develop novel small molecule candidates for the treatment of chronic pain, including neuropathic pain.

Under the terms of the agreement, Merck will have the option to exclusively license a compound from Bionomics for development and commercialization. In return, Bionomics may receive option exercise fees and development and regulatory milestone payments of up to $172 million.

Bionomics may also be eligible for undisclosed royalties on net sales of products from the collaboration. Bionomics retains the right to develop and commercialize certain compounds for which Merck does not exercise its option. The initial period of the research program will be two years. Bionomics will use its ionX drug discovery platform and MultiCore chemistry to identify potential drug candidates.

Dr Deborah Rathjen, CEO and MD, Bionomics, said that, "We are very excited to be working with Merck to define new therapies for chronic and neuropathic pain. Bionomics is continuing to deliver on its business model of strategic partnering for the development and commercialization of selected programs within its pipeline."

Dr Sue O'Connor, VP, neuroscience research, Bionomics, said that, "Merck is a global pharmaceutical company and this research collaboration is a strong validation of our drug discovery platforms."

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account



Survey Box

Should we be cautious of viewing COVID-19 vaccine as silver bullet?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls